An antibody with neutralizing activity against both IGF-IR and IGF-I/insulin-hybrid receptors showed more potent anti-tumor effects than antibodies targeting only the IGF-IR or hybrid receptors in xenograft models (40). This evidence concerns the gene IGF1 and neoplasm.